Navigation Links
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
Date:4/21/2009

by blocking the activity of at least three "inhibitors of apoptosis proteins" or IAPs (including XIAP, c-IAP1, and c-IAP2) to create conditions in which apoptosis can proceed. As such, AT-406 is considered a multi-IAP antagonist. IAPs are key components of the complex cascade of protein signaling that activates enzymes called caspases to initiate breakdown of the cancer cell. AT-406 is thought to mimic the activity of Smac (second mitochondria-derived activator of caspases) by binding to XIAP and preventing it from inhibiting caspase activation. Upon binding, AT-406 induces rapid degradation of cIAP-1/2 proteins and promotes apoptosis through activation of caspase-8 and the death-receptor complex.

AT-406 is in late-stage preclinical development and has demonstrated strong single-agent antitumor activity in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also been shown to work synergistically with conventional chemotherapeutic and targeted agents (such as tyrosine kinase inhibitors) in preclinical tumor models.

Other Research Including AT-101

Ascenta Therapeutics also announced that researchers from the University of Pennsylvania presented results at AACR from an independent laboratory study examining the role of Bcl-2 homology (BH) family proteins in the development of chemotherapy resistance in neuroblastoma (Abstract # 3269). Using human-derived neuroblastoma cell lines, these investigators demonstrated differential resistance patterns to inhibitors of the Bcl-2 family proteins based on the relative BH proteins expressed (specifically, Mcl-1 or Bcl-2). They showed that Ascenta's small molecule pan-Bcl-2 inhibitor, AT-101, had preferential inhibition in Mcl-1 predominant lines. They concluded that compounds with activity against Mcl-1 may be useful in the treatment of high-risk neuroblastoma and warrant further stu
'/>"/>

SOURCE Ascenta Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
2. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
3. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
6. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
7. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
8. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
9. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
10. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
11. Arno Therapeutics Reports 2008 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... observed the fractional quantum Hall effect in bilayer graphene ... be tuned by an electric field. , The ... confined to thin sheets are exposed to large magnetic ... thousands of individual electrons behave as a single system. ... well established, many details of this collective behavior remain ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
Breaking Biology Technology:Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Even geckos can lose their grip 2
... 2011 Vermillion, Inc. (NASDAQ: VRML ), a ... call to give a company update following issuance of the ... Conference Call Information To access ... United States and Canada or +1 303 223-2683 internationally.  The ...
... Calif., April 19, 2011 Life Technologies ... will present at Baird,s 2011 Growth Stock Conference on ... Technologies, Chairman and Chief Executive Officer, will present on ... presentation, which will be available for three weeks following ...
... Today, H. Shep Wild, President and Chief Executive ... company focused on the research and development of ... a company overview to venture capital, pharmaceutical and ... Showcase 2011 hosted by the University of Florida ...
Cached Biology Technology:Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011 2Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011 3Life Technologies to Present at Baird's 2011 Growth Stock Conference 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 3CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 4
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... 2014  Pomerantz LLP has filed a class ... the "Company")(NYSE-MKT: PVCT) and certain of its officers.  ... Court, Middle District of Tennessee ... class consisting of all persons or entities who ... 17, 2013 and May 22, 2014, both dates ...
(Date:7/10/2014)... -- Unisys Corporation,s (NYSE: UIS ) subsidiary in ... that it has been selected by the Dutch Custodial Institutions ... Provision Biometrics solution for penitentiaries across The Netherlands ... a solution based on its open standards-based LEIDA ... is up to seven years, with the new system expected ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... as a means to increase vegetation and preserve aesthetics ... cities, local character and biodiversity, researchers are looking to ... environments that are necessary in lightweight green roof design. ... survive in environments with little water--fit well in green ...
... fresh produce increases, vegetable and fruit producers are ... being challenged to examine traditional production practices in ... impact. A recent focus on both the positive ... across the globe working to find methods that ...
... 31 January 2014 VIB and CD3 (KU Leuven) ... agreement with AstraZeneca for the development of novel MALT1 ... The research teams of Thijs Baens and Peter ... Beyaert (VIB-UGent, Inflammation Research Center) were among the first ...
Cached Biology News:Three native aromatics indicated for use in Mediterranean extensive green roofs 2Nitrogen management studied in greenhouse pepper production 2VIB&CD3 enter into license and collaboration agreement with AstraZeneca for development of MALT1 inhibitor 2
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse TrkC Affinity Purified Polyclonal Ab...
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Biology Products: